MDC Press Release | Muscular Dystrophy Canada calls on provincial governments to prioritize persons affected by neuromuscular disorders for COVID-19 vaccine
Muscular Dystrophy Canada (MDC) have released a statement regarding Canada’s vaccine roll-out plan and the neuromuscular community. MDC advocates that provincial governments prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
February 23, 2021 – Many people living with neuromuscular disorders (NMD) are at greater risk of developing serious symptoms and complications as a result of COVID-19 due to their often pre-existing cardiac and respiratory issues and chronic comorbidities. As the voice of the NMD community in Canada, Muscular Dystrophy Canada (MDC) is calling on governments to prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
“We want governments to recognize the critical need of the NMD community, to ensure that persons with NMDs are specifically noted as high-risk in roll out plans and prioritize their health, just as we do.”
Stacey Lintern, CEO, Muscular Dystrophy Canada.
Read the Full Release Here
Read next...
Save the Date: 2027 Neuromuscular Postdoctoral Fellowship Funding Competition
The 2027 NMD4C/MDC Neuromuscular Postdoc Fellowship Funding Competition will open for applications on September 2, 2026. Our annual funding competition awards salary support for early-career scientists pursuing postdoctoral studies in neuromuscular disease research.
Spinal Muscular Atrophy (SMA) Awareness Month – Research Spotlight
August is Spinal Muscular Atrophy (SMA) Awareness Month, and we are thrilled to feature high-impact research led by members of the NMD4C community!
Published recently in Annals of Neurology, a study titled “Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy” explores the potential of early prenatal therapeutic interventions for SMA.
